Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 27

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 27
---
 Kong, Japan, Israel, Mexico, Russia, and New Zealand.
The patents relating to these technologies will expire no sooner than 2035 or, in the case of the administration methods, 2036.

Also, in March 2015, we executed a sponsored research
agreement with COH, pursuant to which research is performed in the laboratory of Drs. Stephen Forman and Christine Brown. The sponsored
research agreement gives us the right to first negotiation under specified maximum terms regarding any future inventions arising from
the laboratory.

In May 2017, we licensed intellectual property
related to CAR T technology for targeting CD20 from Fred Hutch. The intellectual property includes an international application under
the Patent Cooperation Treaty (i.e., a PCT application), which has now matured into several issued patents, including issued patents in
the U.S. and Europe, as well as pending applications in the U.S., Australia, Brazil, Canada, China, Europe, Hong Kong, Israel, Japan,
South Korea, Mexico, New Zealand, and Russia. These applications contain claims relating to various CD20-targeting CAR constructs and
CAR T cells, as well as methods of making and using the same. The national stage applications claiming priority to the PCT application
were filed in May 2018 in order to begin substantive examination of the claims. Patents maturing from these national stage applications
will expire no sooner than March 2037.

In February 2019, we licensed material and technical
information related to the HSV-1 oncolytic virus C134 from Nationwide in Columbus, Ohio.

<div align='center'>13</div>

​

Table of Contents

In addition to the technology we have in-licensed,
we have also developed our own proprietary intellectual property, both alone and in conjunction with COH. In particular, we own pending
applications in the U.S. and Europe directed to methods for manufacturing cell-based therapeutics, and pending PCT applications, and applications
in the U.S. and Taiwan, relating to anti-idiotype antibodies. We and COH also own, as co-applicants, pending PCT applications, and applications
in the U.S. and Taiwan, directed to methods of treating hematological cancers with a combination therapy.

Other Intellectual Property Rights

We depend upon trademarks, trade secrets, know-how
and continuing technological advances to develop and maintain our competitive position. To maintain the confidentiality of trade secrets
and proprietary information, we require our employees, scientific advisors, consultants and collaborators,